CClinicalTrials.gg
CompletedNCT04518865Updated Aug 19, 2020

Treatment Effects of Herbst Appliance in Skeletal Class II Cases During Prepubertal and Postpubertal Periods

An interventional study of Herbst appliance in Class II Malocclusion, Division 1, sponsored by Al-Azhar University. Completed at 1 site in Egypt. Open to participants aged 8 Years to 17 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-08-19.

Sponsored by Al-Azhar University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 10 months after the study started (first participant enrolled Oct 2017, registered Aug 2020).
Phase
Not applicable
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
8 Years to 17 Years
Sex
All
01

Study summary

The study was directed to compare the treatment outcomes of subjects with Class II malocclusion who were treated with Herbst appliance before and after puberty.

Read the detailed description

Thirty-six Class II patients were randomly selected and divided into two groups based on their stage of skeletal maturation: pre-pubertal group (18 patients, mean age 9.15± 1.5 years) and post-pubertal group (18 patients, mean age 16.3 ± 1.0 years). All patients were treated with metallic splint supported Herbst IV appliance.

Pretreatment and post-Herbst IV treatment cone beam CT(CBCT) scans were obtained for both groups. Dentoskeletal and TMJ measurements made on the CBCT scans were analysed.

02

Conditions studied

  • Class II Malocclusion, Division 1

Keywords

  • Class II malocclusion.
  • prepubertal patients.
  • postpubertal patients.
  • Herbst appliance.
03

In context

Malocclusion

455 studies on the registry are indexed under Malocclusion; 89 are open to participants now.

This study's enrollment of 36 is close to the median of 36 across 371 interventional studies indexed under Malocclusion.

Browse Malocclusion studies →

Lead sponsor

Al-Azhar University is the lead sponsor of 505 studies on the registry; 167 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
8 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  1. Skeletal Class II malocclusion with retrognathic mandible (ANB >5°, SNB\<76°)
  2. Normal growth pattern (SN/MP angle was in 25°- 35° range)
  3. Unilateral or bilateral Class II molar relationship greater than or equal to one-half a cusp width.
  4. Minimal or no crowding in the mandibular arch (0-5mm).
  5. Average inclination or slight retroclination of the lower incisor.
  6. An overjet greater than 5 mm.

Exclusion criteria

Exclusion Criteria:

  1. Skletal Class I
  2. Craniofacial syndrome.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    pre-pubertal group.

    The patients were allocated into the pre-pubertal group based on their skeletal stage of maturation using the modified cervical vertebrae maturation Staging (CVMS) with skeletal maturity stages of CVMS II and CVMS III

    Device: Herbst appliance

  • Experimental
    post-pubertal group

    The patients were allocated into the post-pubertal group based on their skeletal stage of maturation using the modified cervical vertebrae maturation Staging (CVMS) with skeletal maturity stages of CVMS V and CVMS IV

    Device: Herbst appliance

Interventions

  • DeviceHerbst appliance

    The bottom line of the study is to investigate the changes after Herbst appliance treatment and relate it to the pubertal status of the skeletal class II patients using CBCT.

06

What researchers measure

Primary outcomes

  1. Skeletal and dental changes

    The DICOM (Digital Imaging and Communications in Medicine) files from the pre and post CBCT scans were imported to Mimics software (Version 10.1, Materialise NV, Leuven, Belgium); and the cephalometric landmarks and planes were defined . Linear sagittal measurements of point A, point B, glenoid fossa, upper incisor, lower incisor, upper molars, and lower molars were recorded in relation to orbital perpendicular plane.

    Time frame: 8 months

Secondary outcomes

  1. Condylar head position

    The Most middle-superior point of the mandibular condyle was determined in sagittal, axial and coronal views. In the sagittal slice of the middle condylar head, a line was drowned through the widest measurement of the condylar heads visible on the slice, from this line, three lines were raised crossing the glenoid fossa at 45°, 90°, and 135° . Four linear measurements representing the anterosuperior, superior, posterosuperior, and posterior distance were taken from the glenoid fossa wall to the surface of the condyle

    Time frame: 8 months

07

Study locations

1 site
  • Al-Azhar university
    Cairo, Egypt
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 19, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04518865
Lead sponsor
Al-Azhar University
Responsible party
khaled farouk (lecturer, Al-Azhar University) — Principal investigator
First posted
Aug 19, 2020
Start date
Oct 1, 2017
Primary completion
Feb 1, 2019
Completion
Apr 1, 2019
Last update
Aug 19, 2020

Study contacts

khaled Farouk, lecturer
principal investigator · Al-Azhar University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion